Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R Henry

Showing results (111-120 of 155) with videos related to

Pageof 16
Sort By:
Diabetologia|October 17, 2018
Correction to: Mitochondrial H<sup>+</sup>-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistanceLaura Formentini, Alexander J Ryan, Manuel Gálvez-Santisteban, et al.
Clinical Science (London, England : 1979)|May 7, 2013
Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoaPam R Taub, Israel Ramirez-Sanchez, Theodore P Ciaraldi, et al.
Diabetes, Obesity & Metabolism|November 18, 2018
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetesKenneth Cusi, Fernando Bril, Diana Barb, et al.
Diabetologia|August 4, 2017
Mitochondrial H<sup>+</sup>-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistanceLaura Formentini, Alexander J Ryan, Manuel Gálvez-Santisteban, et al.
Gastroenterology|June 4, 2013
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver diseaseSunder Mudaliar, Robert R Henry, Arun J Sanyal, et al.
The Journal of Biological Chemistry|June 3, 2017
Deletion of interleukin 1 receptor-associated kinase 1 (<i>Irak1</i>) improves glucose tolerance primarily by increasing insulin sensitivity in skeletal muscleXiao-Jian Sun, Soohyun Park Kim, Dongming Zhang, et al.
European Heart Journal|July 28, 2016
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studiesHelen M Colhoun, Henry N Ginsberg, Jennifer G Robinson, et al.
Clinical Science (London, England : 1979)|August 25, 2011
Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucoseTodd S Perlstein, Robert R Henry, Kieren J Mather, et al.
Diabetes, Obesity & Metabolism|December 29, 2017
Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trialJeremy Pettus, Dominic Reeds, Tricia S Cavaiola, et al.
Diabetes, Obesity & Metabolism|September 15, 2017
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trialLawrence A Leiter, Bertrand Cariou, Dirk Müller-Wieland, et al.
Pageof 16

Showing results (111-120 of 155) with videos related to

Sort By:
Pageof 16
Diabetologia|October 17, 2018
Correction to: Mitochondrial H<sup>+</sup>-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistanceLaura Formentini, Alexander J Ryan, Manuel Gálvez-Santisteban, et al.
Clinical Science (London, England : 1979)|May 7, 2013
Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoaPam R Taub, Israel Ramirez-Sanchez, Theodore P Ciaraldi, et al.
Diabetes, Obesity & Metabolism|November 18, 2018
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetesKenneth Cusi, Fernando Bril, Diana Barb, et al.
Diabetologia|August 4, 2017
Mitochondrial H<sup>+</sup>-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistanceLaura Formentini, Alexander J Ryan, Manuel Gálvez-Santisteban, et al.
Gastroenterology|June 4, 2013
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver diseaseSunder Mudaliar, Robert R Henry, Arun J Sanyal, et al.
The Journal of Biological Chemistry|June 3, 2017
Deletion of interleukin 1 receptor-associated kinase 1 (<i>Irak1</i>) improves glucose tolerance primarily by increasing insulin sensitivity in skeletal muscleXiao-Jian Sun, Soohyun Park Kim, Dongming Zhang, et al.
European Heart Journal|July 28, 2016
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studiesHelen M Colhoun, Henry N Ginsberg, Jennifer G Robinson, et al.
Clinical Science (London, England : 1979)|August 25, 2011
Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucoseTodd S Perlstein, Robert R Henry, Kieren J Mather, et al.
Diabetes, Obesity & Metabolism|December 29, 2017
Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trialJeremy Pettus, Dominic Reeds, Tricia S Cavaiola, et al.
Diabetes, Obesity & Metabolism|September 15, 2017
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trialLawrence A Leiter, Bertrand Cariou, Dirk Müller-Wieland, et al.
Pageof 16